STE insider sale: 7,900 shares sold; vested option for 7,900 shares at $114.22
Rhea-AI Filing Summary
Karen L. Burton, VP & CAO and a company officer of STERIS plc (STE), reported a sale and an outstanding option in a Form 4 filing. On 08/11/2025 she sold 7,900 ordinary shares at a weighted average price of $241.73 per share (sales ranged from $241.33 to $242.32), reducing her direct beneficial ownership to 5,994 ordinary shares.
She continues to hold a fully vested employee stock option to purchase 7,900 ordinary shares at a strike price of $114.22 that originated from the company’s March 2019 redomiciliation exchange. Of the remaining shares, 3,216 are restricted and vest in scheduled tranches between October 1, 2025 and June 5, 2028.
Positive
- Holds a fully vested employee stock option to purchase 7,900 shares at a strike of $114.22, providing potential long-term alignment with shareholders.
- Sale disclosed with weighted average price range ($241.33–$242.32), increasing transparency about the executed transactions.
Negative
- Sold 7,900 ordinary shares, reducing direct beneficial ownership to 5,994 shares — a material disposition disclosed in the Form 4.
- Only 5,994 shares remain in direct beneficial ownership, of which 3,216 are restricted and subject to a staggered vesting schedule.
Insights
TL;DR: Officer sold 7,900 shares at ~$241.7, retained 5,994 shares and holds a fully vested option for 7,900 shares at $114.22.
The reported sale of 7,900 shares at a weighted average of $241.73 is a significant, discrete insider disposition and reduces direct ownership to 5,994 shares. The filing also discloses a fully vested employee stock option covering 7,900 shares with a $114.22 exercise price that dates to the March 2019 redomiciliation exchange. The combination of a large sale and a sizable vested option means the officer retains meaningful economic exposure and upside potential while realizing proceeds from existing equity. For investors, this is material disclosure of insider activity but does not by itself indicate operational changes at the company.
TL;DR: Form 4 shows routine insider reporting: a sizable sale, retained restricted shares, and a legacy vested option from redomiciliation.
The report is complete in its disclosures: sale price range ($241.33–$242.32), post-transaction beneficial ownership (5,994 shares), and detailed vesting schedule for 3,216 restricted shares. The filing also documents the treatment of a legacy option grant tied to the company’s March 2019 redomiciliation. From a governance standpoint, the disclosure meets Rule 16 reporting requirements and provides transparent vesting and option information for stakeholders assessing insider alignment.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 7,900 | $0.00 | -- |
| Exercise | Ordinary Shares | 7,900 | $114.22 | $902K |
| Sale | Ordinary Shares | 7,900 | $241.73 | $1.91M |
Footnotes (1)
- Price reflects a weighted average sale price for multiple transactions ranging from $241.33 to $242.32 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. As of August 12, 2025, 3,216 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 86 on October 1, 2025; 340 on June 1, 2026; 651 on June 3, 2026; 225 on June 2, 2026; 306 on June 4, 2026; 651 on June 3, 2027; 306 on June 4, 2027 and 651 on June 5, 2028. This option to purchase 7,900 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 7,900 ordinary shares for $114.22 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option.
